Condition: Cirrhosis · Cirrhosis, Liver · Cirrhosis Early · Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
This description comes directly from the study's public registry record.
Crystal Santillanes, MS · 312-503-5536 · lcn@northwestern.edu
Mary Beth Tull, MBA, CCRP · 312-503-4746 · mary.tull@northwestern.edu
Always discuss trial participation with your own doctor first.
| University of California San Diego NAFLD Research Center | La Jolla, California, United States | Recruiting |
| Keck Medical Center of USC | Los Angeles, California, United States | Recruiting |
| LAC + USC Medical Center | Los Angeles, California, United States | Recruiting |
| UCSF/Zuckerberg San Francisco General Hospital and Trauma Center | San Francisco, California, United States | Recruiting |
| UCSF Medical Center | San Francisco, California, United States | Recruiting |
| University of Miami Health System | Miami, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| New York Presbyterian/Weill Cornell | New York, New York, United States | Recruiting |
| Columbia University Iriving School of Medicine | New York, New York, United States | Recruiting |
| Duke Liver Center | Durham, North Carolina, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Active Not Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05832229